Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. BALTIMORE, June 18, 2025--(BUSINESS WIRE)--Infinity Bio, a ...

BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a leading provider of advanced antibody reactome profiling services, is excited to announce the creation of its Scientific Advisory Board (SAB). This new ...

Infinity Bio service offerings leverage proprietary MIPSA technology to provide unprecedented insights into antibody reactivity for translational research and therapeutic development. BALTIMORE, ...

Infinity Bio takes a business-to-business approach to pharmaceuticals. Here's more on the company and its growth. A Johns Hopkins University spinout has opened a 9,000-square-foot lab in East ...

BALTIMORE--(BUSINESS WIRE)--Infinity Bio is pleased to announce the release of their MuSIGHT™ mouse autoantibody reactome service offering. Defining an animal’s autoantibody reactome – the set of all ...

) -- @atrini opens this week's Biotech Stock Mailbag by asking: "Are you expecting any news on CYT387 at ASH in December?" ( YMI) will release final nine-month results from the 166-patient phase II ...

Infinity Bio is a technology company that provides detailed insights into the immune system using its proprietary core technology that comprehensively measures the antibody reactome, revealing the ...

The MarketWatch News Department was not involved in the creation of this content. Infinity Bio service offerings leverage proprietary MIPSA technology to provide unprecedented insights into antibody ...